2m 2m 2m 2m 2m 2m 2m
ABEONA THERAP (ABEO)
NASDAQ
$5.69+$0.02 (+0.30%)
Price as of Jun 03, 2026 7:55 PM EDT- $329.4MMarket Cap
- -9.25%1-Year Change
- BiotechnologyIndustry
ABEONA THERAP (ABEO)
$5.69+$0.02 (+0.30%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 2.4M -43.01% | 4.2M +21.31% | 3.5M +147.52% | 1.4M -52.87% | |
Cost of Revenue | 1.5M N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 888,000 -79.09% | 4.2M +21.31% | 3.5M +147.52% | 1.4M -52.87% | |
Sales and Marketing Expense | 65.0M N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -26.8M -21.97% | -34.4M +10.51% | -31.1M +7.34% | -29.0M -15.62% | |
Depreciation and Amortization Expense | 2.5M +27.20% | 2.0M -12.41% | 2.3M -26.03% | 3.1M -4.83% | |
Total Operating Expenses | 95.3M +48.37% | 64.2M +26.81% | 50.6M -3.24% | 52.3M -43.63% | |
Operating Profit | -89.4M +39.30% | -64.2M +36.23% | -47.1M -7.42% | -50.9M -43.32% | |
Interest Income | 5.6M +30.85% | 4.2M +100.57% | 2.1M +391.18% | 431,000 N/A | |
Interest Expense | -3.7M -11.12% | -4.2M +906.70% | -418,000 -43.21% | -736,000 -79.95% | |
Interest Income and Expense and Net | 1.8M +4,678.95% | 38,000 -97.76% | 1.7M +657.05% | -305,000 -91.69% | |
Total Nonoperating Income and Expense | 410,000 -65.66% | 1.2M -59.43% | 2.9M +299.86% | 736,000 -79.95% | |
Income before Taxes | 71.3M +211.01% | -64.2M +18.50% | -54.2M +24.63% | -43.5M -51.60% | |
Income Taxes | 100,000 N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | 1.8M 0.00% | 1.8M N/A | |
Net Income | 71.3M +212.02% | -63.7M +17.48% | -54.2M +36.51% | -39.7M -53.26% | |
Net Income from Continuing Operations Applicable to Common | 71.3M +211.90% | -63.7M +17.55% | -54.2M +24.63% | -43.5M -48.81% | |
Basic EPS and Net Income | 1.34 +186.45% | -1.55 -38.74% | -2.53 -54.25% | -5.53 +543.02% | |
Diluted EPS and Net Income | 1.01 +165.16% | -1.55 -38.74% | -2.53 -54.25% | -5.53 +543.02% | |
Basic Weighted Average Shares | 53.0M +29.00% | 41.0M +91.99% | 21.4M +171.96% | 7.9M -92.01% | |
Diluted Weighted Average Shares | 66.1M +61.12% | 41.0M +91.99% | 21.4M +171.96% | 7.9M -92.01% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 78.4M +235.82% | 23.4M +61.38% | 14.5M +1.80% | 14.2M -56.84% | |
Short-Term Investments | 113.0M +51.91% | 74.4M +96.97% | 37.8M -0.47% | 37.9M +213.85% | |
Cash and Cash Equivalents and Short-Term Investments | 191.4M +95.87% | 97.7M +87.11% | 52.2M +0.15% | 52.1M +15.82% | |
Total Current Assets | 204.9M +103.17% | 100.9M +80.94% | 55.7M +4.97% | 53.1M -4.16% | |
Accumulated Depreciation | 17.2M +14.94% | 15.0M +15.31% | 13.0M +9.36% | 11.9M +13.57% | |
Property and Plant and Equipment and Net | 9.9M +123.95% | 4.4M +25.39% | 3.5M -38.46% | 5.7M -53.47% | |
Total Long-Term Assets | 781,000 +713.54% | 96,000 -65.34% | 277,000 +544.19% | 43,000 -99.65% | |
Total Assets | 219.6M +101.57% | 108.9M +70.20% | 64.0M -0.33% | 64.2M -19.31% | |
Income Taxes Payable | 126,000 N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 12.2M +106.24% | 5.9M N/A | N/A N/A | 10.0M +117.44% | |
Total Current Liabilities | 29.6M +78.27% | 16.6M +23.58% | 13.4M +72.54% | 7.8M -53.20% | |
Total Long-Term Debt | 7.8M -40.07% | 13.0M +183.41% | 4.6M +10.50% | 4.2M +8.75% | |
Total Long-Term Liabilities | 30.8M +88.87% | 16.3M +270.26% | 4.4M -24.80% | 5.9M +2,827.00% | |
Total Liabilities | 60.4M -7.00% | 64.9M +31.97% | 49.2M +31.30% | 37.5M +32.76% | |
Retained Earnings | -742.1M -8.75% | -813.3M +8.50% | -749.5M +7.79% | -695.3M +6.05% | |
Total Stockholders Equity | 159.2M +261.60% | 44.0M +196.99% | 14.8M -44.60% | 26.8M -47.91% | |
Total Shares Outstanding | 55.0M +20.59% | 45.6M +72.09% | 26.5M +49.69% | 17.7M -87.96% | |
Cash Flow | |||||
Cash from Operating Activities | -76.3M +36.26% | -56.0M +51.36% | -37.0M -14.89% | -43.5M -33.78% | |
Capital Expenditures | 8.0M +226.04% | 2.4M +638.97% | 331,000 +154.62% | 130,000 -96.87% | |
Cash from Investing Activities | 105.0M +367.66% | -39.2M -18,965.38% | 208,000 +100.87% | -24.0M -136.28% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 26.0M -74.99% | 104.1M +181.02% | 37.1M -14.17% | 43.2M +73.66% | |
Financials Ratio | |||||
Gross Margin | 36.69% N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -3,696.20% +144.41% | -1,512.27% +12.29% | -1,346.71% -62.60% | -3,600.78% +20.25% | |
Return on Assets | 43.42% +158.97% | -73.62% -12.90% | -84.53% +53.10% | -55.21% -24.99% | |
Return on Equity | 70.17% +132.44% | -216.32% -16.99% | -260.60% +156.48% | -101.61% -7.93% | |
Revenue Growth | -43.01% -301.77% | 21.31% -85.55% | 147.52% +379.05% | -52.87% -24.48% | |
Current Ratio | 6.93 +13.97% | 6.08 +46.42% | 4.15 -39.16% | 6.83 +104.81% | |
Cash Ratio | 2.65 +88.37% | 1.41 +30.59% | 1.08 -41.00% | 1.83 -7.77% | |
Debt-to-Equity Ratio | 0.13 -70.79% | 0.43 N/A | N/A N/A | 0.53 +222.68% | |
Debt-to-Assets Ratio | 0.09 -47.62% | 0.17 N/A | N/A N/A | 0.22 +108.31% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow